Presentation is loading. Please wait.

Presentation is loading. Please wait.

Date of download: 5/27/2016 From: Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial Ann Intern Med. 2013;158(9):641-649.

Similar presentations


Presentation on theme: "Date of download: 5/27/2016 From: Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial Ann Intern Med. 2013;158(9):641-649."— Presentation transcript:

1 Date of download: 5/27/2016 From: Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial Ann Intern Med. 2013;158(9):641-649. doi:10.7326/0003-4819-158-9-201305070-00003 Schematic of profibrotic pathways that may be modulated by endothelin receptor antagonists. α-SMA = α-smooth muscle actin; CCN2 = connective tissue growth factor; ECM = extracellular matrix; EMT = epithelial–mesenchymal transition; ET-1 = endothelin-1; MMP-1 = matrix metalloproteinase-1; SMC = smooth muscle cell; TGF-β = transforming growth factor-β. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2 Date of download: 5/27/2016 From: Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial Ann Intern Med. 2013;158(9):641-649. doi:10.7326/0003-4819-158-9-201305070-00003 Study flow diagram. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3 Date of download: 5/27/2016 From: Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial Ann Intern Med. 2013;158(9):641-649. doi:10.7326/0003-4819-158-9-201305070-00003 Kaplan–Meier plots for disease progression (A) (P = 0.010) and its components (lung function decline [B] [P = 0.109], respiratory hospitalizations [C] [P = 0.007], and death [D] [P = 0.100]), by treatment group. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

4 Date of download: 5/27/2016 From: Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial Ann Intern Med. 2013;158(9):641-649. doi:10.7326/0003-4819-158-9-201305070-00003 Mean change from baseline for FVC (top), Dlco(middle), and 6MWD (bottom), by treatment group. Dlco = diffusion capacity for carbon monoxide; 6MWD = 6-min walk distance. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians


Download ppt "Date of download: 5/27/2016 From: Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial Ann Intern Med. 2013;158(9):641-649."

Similar presentations


Ads by Google